Page 32 - Aet News Today

As we look into the future, 2024 promises a profound transformation. Here are five areas of focus for the upcoming year.

Contraline released promising data from the clinical trial it’s conducting to test the efficacy of Adam, its male birth control product. The nonhormonal gel seems to be doing a good job of blocking the flow of sperm to the vas deferens, and no serious adverse events have been reported.

On New Year’s Day, two Missouri health systems — St. Louis-based BJC HealthCare and Kansas City-based St. Luke’s Health System — officially completed their merger. The combined health system comprises 28 hospitals and hundreds of clinics serving 6 million people, and it is expected to generate $10 billion in annual revenue.

Aetna Better Health of Kentucky, Avēsis and MapHabit have teamed up to support 200 Kentucky children with autism or intellectual disabilities. The pilot program will help the patients with activities of daily living, such as oral hygiene.

The evolution of ECMO from a last-resort intervention to a mainstay of modern critical care is a testament to the relentless pursuit of better patient outcomes in the field of medicine. Unfortunately, despite the immense life-saving capability of this therapy, it remains vastly underutilized.

How UPMC Health Plan is taking steps in providing better behavioral health support.

Mount Sinai is out of network for UnitedHealthcare's employer-sponsored and individual plans as of January 1 due to a payment dispute. Both parties are likely at fault for getting to this point, one expert declared.

Patient Reported Outcome Measures (PROM) scores should be the gold standard for how patients find their doctors, not viewing subjective online reviews of doctors’ ability to satisfy their patients.

A recent Deloitte report found that improving health equity is a top-10 goal for 83% of life sciences and healthcare C-suite executives in 2024. The report also laid out factors that will likely influence health equity in 2024, including AI.

Longboard Pharmaceuticals’ epilepsy drug candidate bexicaserin met the main efficacy goal of its Phase 1b/2a study along with safety data suggesting a potential edge over current treatments. With Longboard now preparing to advance to Phase 3 testing, its stock price soared more than 300%.